Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

552
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
552
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

278
Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
278
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

432
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
432
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

243
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
243
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

3.0K
Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
3.0K
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

338
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
338

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trimethylamine N-oxide (TMAO): a new attractive target to decrease cardiovascular risk.

Postgraduate medical journal·2021
Same author

A Novel, Orally Delivered Antibody Therapy and Its Potential to Prevent <i>Clostridioides difficile</i> Infection in Pre-clinical Models.

Frontiers in microbiology·2020
Same author

Food reinforcement and delay discounting in zBMI-discordant siblings.

Appetite·2014
Same author

Recombinant antigens based on toxins A and B of Clostridium difficile that evoke a potent toxin-neutralising immune response.

Vaccine·2013
Same author

The arthritis-associated HLA-B*27:05 allele forms more cell surface B27 dimer and free heavy chain ligands for KIR3DL2 than HLA-B*27:09.

Rheumatology (Oxford, England)·2013
Same author

HLA-B27 homodimers and free H chains are stronger ligands for leukocyte Ig-like receptor B2 than classical HLA class I.

Journal of immunology (Baltimore, Md. : 1950)·2012

Related Experiment Video

Updated: Sep 29, 2025

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.7K

Clostridioides difficile: Current overview and future perspectives.

Joanna Giles1, April Roberts2

  • 1MicroPharm Ltd, Newcastle Emlyn, United Kingdom.

Advances in Protein Chemistry and Structural Biology
|March 20, 2022
PubMed
Summary

Clostridioides difficile (C. difficile) infections cause significant antibiotic-associated diarrhea. New treatments combining therapies are emerging to combat recurrence and improve patient outcomes.

Keywords:
Antibiotic resistanceC. difficileCDICDI diagnosisCDI treatmentFecal transplantationImmunotherapy of CDIMicrobiotaOral antibodies

More Related Videos

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.1K
Culturing and Maintaining Clostridium difficile in an Anaerobic Environment
11:13

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment

Published on: September 14, 2013

39.1K

Related Experiment Videos

Last Updated: Sep 29, 2025

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.7K
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.1K
Culturing and Maintaining Clostridium difficile in an Anaerobic Environment
11:13

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment

Published on: September 14, 2013

39.1K

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Gastroenterology

Background:

  • Clostridioides difficile (C. difficile) is a leading cause of antibiotic-associated infectious diarrhea and colitis worldwide.
  • The bacterium produces toxins contributing to a wide spectrum of disease, from mild diarrhea to severe colitis.
  • Diagnosis can be challenging despite available sensitive and specific tools.

Purpose of the Study:

  • To review the characteristics, epidemiology, and pathogenesis of C. difficile infections.
  • To discuss diagnostic challenges, disease recurrence, and prevention strategies.
  • To outline current, emerging, and future treatment options for C. difficile.

Main Methods:

  • Literature review of C. difficile infection (CDI) background, epidemiology, pathogenesis, diagnosis, and treatment.
  • Analysis of current therapeutic strategies, including antibiotics, microbial replacement, and monoclonal antibodies.
  • Exploration of novel and future treatment avenues such as new antibiotics, vaccines, and microbiota-targeted therapies.

Main Results:

  • C. difficile infections present a broad clinical spectrum and diagnostic difficulties.
  • High recurrence rates necessitate continuous review and development of treatment strategies.
  • Emerging therapies include pulsed antibiotics, microbial replacement, and monoclonal antibodies.

Conclusions:

  • Future C. difficile management will likely involve combination therapies.
  • Novel approaches include new antibiotics, polyclonal antibodies, vaccines, and microbiota-level interventions.
  • Effective C. difficile treatment requires a multifaceted and robust therapeutic strategy.